NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT02460419,Maintenance Capecitabine Plus Best Supportive Care Versus Best Supportive Care for Metastatic Nasopharyngeal Carcinoma,https://clinicaltrials.gov/study/NCT02460419,,COMPLETED,"This multicenter, randomised, phase 3 study is to evaluate the survival benefit of maintenance capecitabine plus best supportive care versus best supportive care for metastatic nasopharyngeal carcinoma patients after disease controlled with TPC palliative chemotherapy.",NO,Nasopharyngeal Carcinoma,DRUG: capecitabine|OTHER: Best supportive care (BSC),"progression-free survival, the time from randomization to the progression of disease, up to 6 years","overall survival, the time from randomization to death, up to 6 years|duration of response, the time from the date of the first cycle of chemotherapy to the progression of disease, up to 6 years|objective response rate, CR, PR and SD rate, up to 6 years|adverse effects, chemotherapy side effects, up to 6 years|quality of life of the patients during the Maintenance Capecitabine and/or Best Supportive Care, evaluate with FACT-H\&N every 3 months after randomiztion, up to 6 years",,Sun Yat-sen University,Affiliated Cancer Hospital & Institute of Guangzhou Medical University|Affiliated Cancer Hospital of Shantou University Medical College,ALL,"ADULT, OLDER_ADULT",PHASE3,104,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2015029,2015-04,2020-05,2020-05,2015-06-02,,2022-10-28,"SunYat-senU, Guangzhou, Guangdong, 510060, China",
